IN2012DN00765A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00765A
IN2012DN00765A IN765DEN2012A IN2012DN00765A IN 2012DN00765 A IN2012DN00765 A IN 2012DN00765A IN 765DEN2012 A IN765DEN2012 A IN 765DEN2012A IN 2012DN00765 A IN2012DN00765 A IN 2012DN00765A
Authority
IN
India
Prior art keywords
medicament
compound
formula
well
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Li Chen
Lichun Feng
Mengwei Huang
Jia Li
Fajun Nan
Tao Pang
Lifang Yu
Mei Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN00765A publication Critical patent/IN2012DN00765A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN765DEN2012 2009-09-21 2010-09-20 IN2012DN00765A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2009/074060 WO2011032320A1 (fr) 2009-09-21 2009-09-21 Nouveaux dérivés alcényliques d'oxoindole
PCT/EP2010/063770 WO2011033099A1 (fr) 2009-09-21 2010-09-20 Dérivés d'alcène-oxindole et leurs utilisations pour traiter l'obésité, le diabète et l'hyperlipidémie

Publications (1)

Publication Number Publication Date
IN2012DN00765A true IN2012DN00765A (fr) 2015-06-26

Family

ID=43414813

Family Applications (1)

Application Number Title Priority Date Filing Date
IN765DEN2012 IN2012DN00765A (fr) 2009-09-21 2010-09-20

Country Status (10)

Country Link
US (3) US20110071195A1 (fr)
EP (1) EP2480530A1 (fr)
JP (1) JP2013505281A (fr)
KR (1) KR20120068876A (fr)
AU (1) AU2010297252A1 (fr)
BR (1) BR112012006172A2 (fr)
CA (1) CA2772674A1 (fr)
IN (1) IN2012DN00765A (fr)
MX (1) MX2012002477A (fr)
WO (2) WO2011032320A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011032320A1 (fr) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Nouveaux dérivés alcényliques d'oxoindole
US20150005353A1 (en) * 2012-02-10 2015-01-01 Virginia Commonwealth University 3-(2-amino-ethyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-alkylidene-1,3-dihydro-indol-2-one derivatives as selective sphingosine kinase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2769974A1 (fr) * 2013-02-21 2014-08-27 Debiopharm S.A. Nouveau composé activateur de l'AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014202528A1 (fr) * 2013-06-20 2014-12-24 Boehringer Ingelheim International Gmbh Oxindoles substitués par oléfine ayant une activité sur ampk
EP2886541A1 (fr) * 2013-12-19 2015-06-24 Sanofi Dérivés d'oxindole, leur préparation et leur utilisation thérapeutique pour traiter les troubles liés à l'AMPK
ES2567105B1 (es) * 2014-09-19 2017-02-10 Consejo Superior De Investigaciones Científicas (Csic) Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados
CN106619616A (zh) * 2015-11-04 2017-05-10 中国科学院上海药物研究所 3-烯基吲哚酮类衍生物在制备治疗miri药物中的用途及其药物组合物
EP4153589A4 (fr) 2020-05-19 2024-06-12 Kallyope, Inc. Activateurs d'ampk
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201266T3 (es) * 1996-01-17 2004-03-16 Taiho Pharmaceutical Company Limited Inhibidores del espesamiento de la capa intima.
EP0984930B1 (fr) * 1997-05-07 2005-04-06 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JPWO2007032371A1 (ja) * 2005-09-14 2009-03-19 大日本住友製薬株式会社 摂食調節剤としてのオキシインドール誘導体
AU2007294686B2 (en) * 2006-09-15 2013-10-31 Equinox Sciences, Llc Kinase inhibitor compounds
ES2553340T3 (es) * 2007-12-12 2015-12-07 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
KR20100115789A (ko) * 2008-02-04 2010-10-28 머큐리 테라퓨틱스, 인코포레이티드 Ampk 조절자
CN102271509A (zh) * 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
WO2011032320A1 (fr) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Nouveaux dérivés alcényliques d'oxoindole

Also Published As

Publication number Publication date
EP2480530A1 (fr) 2012-08-01
US20110071195A1 (en) 2011-03-24
US20130131114A1 (en) 2013-05-23
JP2013505281A (ja) 2013-02-14
US20140288127A1 (en) 2014-09-25
MX2012002477A (es) 2012-03-26
US8778973B2 (en) 2014-07-15
KR20120068876A (ko) 2012-06-27
CA2772674A1 (fr) 2011-03-24
WO2011033099A1 (fr) 2011-03-24
WO2011032320A1 (fr) 2011-03-24
AU2010297252A1 (en) 2012-02-02
BR112012006172A2 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
IN2012DN00765A (fr)
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
MX2022007264A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
UA108105C2 (ru) Азотсодержащие гетероарильные соединения
IN2012DN03337A (fr)
MX2011012739A (es) Derivados fluorados de aminotriazol.
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
MY153985A (en) Aminotriazole derivatives as alx agonists
MX2011011094A (es) Derivados de prolina como inhibidores de catepsina.
ZA201002987B (en) Tropane compounds
MY183312A (en) Pharmaceutical formulation
IN2012DN03182A (fr)
UA109037C2 (uk) Триазолопіридини
IN2012DN01232A (fr)
PH12015502429A1 (en) Dicarboxylic acid compound
MX349373B (es) Nuevos derivados de pirazina.
NZ595705A (en) Protease inhibitors
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
JO2781B1 (en) A new process for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acid.
IN2014DN10669A (fr)
MX2013008256A (es) Derivados novedosos de tetrahidroquinolina.
MX346090B (es) Derivados de pirrolidina usados como inhibidores de catepsina.
MX2011011716A (es) Derivados de isoquinolina novedosos.
MX2014008918A (es) Nuevos derivados de pirrolidina.
JO2782B1 (en) A new process for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acid.